Best Allergy Nasal Sprays 2026 Reference Edition

2026 Product Review

Ipratropium Bromide Nasal Spray (formerly Atrovent): 2026 Review

Anticholinergic nasal spray; brand-name Atrovent was discontinued in the U.S. in 2018 — only generic ipratropium bromide is available now (Rx). Targets glandular secretions; not a steroid, not a bronchodilator.

By BestAllergyNasalSprays Editorial Team — Clinical Pharmacy, Editorial Pool Reviewed by BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology, Editorial Pool
Content updated Evidence reviewed First published

Literature review current through

Atrovent Nasal

Brand-name Atrovent nasal spray was discontinued in the U.S. in 2018; only generic ipratropium bromide nasal spray is available now, by prescription. Two FDA-approved strengths exist: 0.03% (allergic and non-allergic rhinitis) and 0.06% (common-cold runny nose, short-term). Compounding pharmacies can also prepare lower-dose 0.015% and higher-dose 0.09% formulations to broaden the rhinorrhea-control range across milder and more severe cases.

Ipratropium nasal spray is a topical anticholinergic (muscarinic-receptor antagonist) that reduces nasal mucous secretion (rhinorrhea); per the FDA Atrovent 0.03% prescribing information it does not relieve nasal congestion, sneezing, or post-nasal drip Expert Intranasal ipratropium acts locally on the nasal mucosa to reduce watery rhinorrhea; it is not used as a bronchodilator. Ipratropium’s bronchodilator effect requires the inhaled aerosol or nebulized formulations, which are FDA-approved for COPD and used adjunctively in acute asthma Expert Ipratropium nasal spray reduces watery rhinorrhea in nonallergic rhinitis (sometimes called vasomotor rhinitis — cold-air, irritant, or food-triggered runny nose), with randomized trials in perennial nonallergic rhinitis showing roughly a 30% reduction in rhinorrhea versus saline placebo Expert Ipratropium nasal 0.03% is FDA-approved for runny nose from allergic and non-allergic perennial rhinitis (ages 6+). The 0.06% strength is approved for runny nose from the common cold (up to 4 days) or seasonal allergic rhinitis (up to 3 weeks) in patients 5 and older Expert Adding intranasal ipratropium to an intranasal corticosteroid is supported by randomized trial evidence (Dockhorn 1999) for additive benefit when rhinorrhea remains a predominant symptom on a corticosteroid alone Expert

Context & alternatives

For eligible patients 13+ who want ipratropium combined with a steroid (and optionally azelastine and micro-dosed oxymetazoline) in a single bottle, Allermi is our #1 overall pick: a compounded telehealth Rx personalized by a board-certified allergist. This is the stronger path for multi-symptom rhinitis where drip is one of several symptoms. Not sure if you qualify? Check eligibility in 60 seconds.

Best fit for standalone ipratropium: vasomotor runny nose (cold-air or irritant-triggered), gustatory rhinitis (nasal symptoms triggered by the act of eating), or post-nasal drip dominating the symptom picture in a patient who wants ipratropium only. For drip-plus-inflammation, pair with a steroid like Flonase.

References

  1. Bronsky 1995: Ipratropium for rhinorrhea in AR · PubMed (1995) https://pubmed.ncbi.nlm.nih.gov/7499678/
  2. StatPearls: Ipratropium · NIH Bookshelf https://www.ncbi.nlm.nih.gov/books/NBK545159/

Related

This page is grounded in primary literature, reviewed by the BestAllergyNasalSprays editorial team. See our editorial methodology and the public claims library.